The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)

N/ACompletedNCT01206257

Bayer17,513 enrolled

Overview

This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity

Study Type

OBSERVATIONAL

Enrollment

17,513

Conditions

Angiocardiography

Interventions

Iopromide (Ultravist, BAY86-4877)DRUG

Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Female and male patients who receive Ultravist® for coronary angiography or PCI can be included in the study Exclusion Criteria: * Patients who are or are suspected in pregnancy or nursery * Patients with the contraindications for Ultravist * Patients with the contraindications for cardiac catheterization

Locations (1)

Unnamed facility

Many Locations, China

Outcomes

Primary Outcomes

Evaluation of the safety and tolerability of Ultravist® in patients Undergoing cardiac catheterization.

Time frame: 12 months

Secondary Outcomes

Estimation of the image quality of Ultravist®

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.